Pyrimethamine showed on-target activity, as assessed by inhibition of expression of STAT3-dependent genes, in a clinical trial of chronic lymphocytic leukemia (10), a disease in which the leukemia cells are nearly always driven by increased STAT3 transcriptional activity. This evidence concerns the gene STAT3 and B-cell chronic lymphocytic leukemia.